The journey of Advanced Therapy Medicinal Product (ATMP) studies in the European Union

Sponsors developing combined advanced therapy medicinal products (CATMPs) play an important role in advancing potentially groundbreaking opportunities and addressing unmet healthcare needs.

Diversity Action Plans: What sponsors need to know about the latest FDA guidance

The FDA’s much-anticipated Diversity Action Plan guidance was published on June 26th, 2024. This is still a draft guidance with a comment period of 90 days; Fortrea’s Diversity Workstream group will be working with Fortrea’s Regulatory Intelligence team to compile comments and submit them to the FDA.

Importance of patient perspectives in neurology clinical trials

Incorporating patient perspectives through interviews in neurology clinical trials
 

It is never too early to start a strategic plan for oncology product development in the APAC region

In oncology, a goal-oriented, holistic strategic plan is crucial, even in the earliest phases of product development. 

Empowering young voices in pediatric clinical trials: Fortrea’s commitment to child rights and participation

Learn about the experiences of the young participants involved in the clinical trials.

Celebrating Clinical Trials Day: A look back to move forward

Patient-Centric Solutions for Cell and Gene Therapy Trials

A Scientific Journey in the Midst of the Russia/Ukraine Conflict

Fortrea's efforts in continuing scientific research and clinical trials amidst the challenges posed by the Russia-Ukraine conflict.

Beauty & Personal Care: Towards a Sustainable Future

Discover Fortrea's research on beauty and personal care, focusing on sustainable trends. Read our blog for insights into the future of beauty and personal care.

Rare diseases: A spotlight on Gaucher disease research in India

Explore Fortrea's focus on Gaucher disease research in India, addressing rare diseases with innovative treatment approaches.